Ad­comm mem­ber who warned about risk of ap­prov­ing Bio­gen's ad­u­canum­ab has re­signed fol­low­ing his­toric OK — re­ports

One of the 11 ex­perts the FDA had con­vened to dis­cuss Bio­gen’s ad­u­canum­ab — be­fore over­rid­ing their rec­om­men­da­tion and ap­prov­ing the Alzheimer’s drug — has re­signed from the pan­el, STAT News and Pink Sheet re­port­ed.

Joel Perl­mut­ter, a neu­rol­o­gist at Wash­ing­ton Uni­ver­si­ty in St. Louis who’s been on the Pe­riph­er­al & Cen­tral Ner­vous Sys­tem Drugs Ad­vi­so­ry Com­mit­tee ros­ter since 2015, told STAT that he quit on Mon­day “due to this rul­ing by the FDA with­out fur­ther dis­cus­sion with our ad­vi­so­ry com­mit­tee.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER